Business Description
Natco Pharma Ltd
SIC : 2834
ISIN : INE987B01026
Share Class Description:
BOM:524816: Ordinary SharesTotal Employee Number:
4,955Compare
Compare
Traded in other countries / regions
524816.India IPO Date
1995-04-17Description
Natco Pharma Ltd is engaged in the development, manufacturing, and marketing of Finished Dosage Formulations (FDFs), Active Pharmaceutical Ingredients (APIs), and Agrochemicals. The Group's API business develops cGMP-compliant drug substances, with oncology as its core therapeutic area, along with CNS, pain management, and cardiovascular care. The FDFs portfolio comprises products across neurology, oncology, hepatology, infectious diseases, cardiology, and other areas, and the Agrochemicals business offers insecticides, fungicides, plant growth promoters, herbicides, and other related products. Its reportable segments are Pharmaceuticals, which derives key revenue, and Agro Chemicals. Geographically, the Group derives maximum revenue from the USA, and the rest from India and other markets.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.91 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | 0.53 | |||||
Interest Coverage | 18.41 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 6.71 | |||||
Beneish M-Score | -1.95 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.2 | |||||
3-Year EBITDA Growth Rate | 19.3 | |||||
3-Year EPS without NRI Growth Rate | 27.1 | |||||
3-Year FCF Growth Rate | 29.7 | |||||
3-Year Book Growth Rate | 24.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.34 | |||||
9-Day RSI | 25.59 | |||||
14-Day RSI | 29 | |||||
3-1 Month Momentum % | 5.97 | |||||
6-1 Month Momentum % | -4.62 | |||||
12-1 Month Momentum % | 5.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.01 | |||||
Quick Ratio | 2.47 | |||||
Cash Ratio | 1.66 | |||||
Days Inventory | 501.21 | |||||
Days Sales Outstanding | 134.31 | |||||
Days Payable | 240.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.8 | |||||
Dividend Payout Ratio | 0.08 | |||||
3-Year Dividend Growth Rate | -3.1 | |||||
Forward Dividend Yield % | 0.74 | |||||
5-Year Yield-on-Cost % | 0.82 | |||||
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | -0.87 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.64 | |||||
Operating Margin % | 24.56 | |||||
Net Margin % | 32.84 | |||||
EBITDA Margin % | 38.66 | |||||
FCF Margin % | 46.75 | |||||
OCF Margin % | 57.89 | |||||
ROE % | 13.47 | |||||
ROA % | 11.39 | |||||
ROIC % | 12.46 | |||||
3-Year ROIIC % | 13.97 | |||||
ROC (Joel Greenblatt) % | 27.57 | |||||
ROCE % | 13.38 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 12.73 | |||||
Forward PE Ratio | 22.03 | |||||
PE Ratio without NRI | 12.73 | |||||
Shiller PE Ratio | 14.46 | |||||
Price-to-Owner-Earnings | 7.37 | |||||
PEG Ratio | 0.34 | |||||
PS Ratio | 4.18 | |||||
PB Ratio | 1.58 | |||||
Price-to-Tangible-Book | 1.62 | |||||
Price-to-Free-Cash-Flow | 10.57 | |||||
Price-to-Operating-Cash-Flow | 8.24 | |||||
EV-to-EBIT | 10.85 | |||||
EV-to-EBITDA | 9.27 | |||||
EV-to-Forward-EBITDA | 9.96 | |||||
EV-to-Revenue | 3.58 | |||||
EV-to-Forward-Revenue | 4.6 | |||||
EV-to-FCF | 9.09 | |||||
Price-to-GF-Value | 0.99 | |||||
Price-to-Projected-FCF | 0.92 | |||||
Price-to-DCF (Earnings Based) | 0.61 | |||||
Price-to-DCF (FCF Based) | 0.41 | |||||
Price-to-Median-PS-Value | 0.74 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.51 | |||||
Price-to-Graham-Number | 0.86 | |||||
| Price-to-Net-Current-Asset-Value | 4.55 | |||||
| Price-to-Net-Cash | 15.57 | |||||
Earnings Yield (Greenblatt) % | 9.22 | |||||
FCF Yield % | 9.46 | |||||
Forward Rate of Return (Yacktman) % | 24.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Natco Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 34,846 | ||
| EPS (TTM) (₹) | 63.888 | ||
| Beta | 1.1668 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.11 | ||
| Volatility % | 30.89 | ||
| 14-Day RSI | 29 | ||
| 14-Day ATR (₹) | 21.932409 | ||
| 20-Day SMA (₹) | 846.555 | ||
| 12-1 Month Momentum % | 5.81 | ||
| 52-Week Range (₹) | 789.3 - 1226.1 | ||
| Shares Outstanding (Mil) | 182.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Natco Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Natco Pharma Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-02-12 16:00 | In 149 days | ||
| Third quarter earnings results for 2027 | 2027-02-12 | In 148 days | ||
| Second quarter earnings conference call for 2027 | 2026-11-13 16:30 | In 58 days | ||
| Second quarter earnings results for 2027 | 2026-11-13 | In 57 days | ||
| General meeting for 2026 | 2026-09-30 11:00 | In 14 days | ||
| Annual report for 2026 | 2026-09-04 | 838.05 (-1.75%) | ||
| INR 1.500000 Cash Dividend | 2026-08-20 | 887.05 (-1.44%) | ||
| First quarter earnings conference call for 2027 | 2026-08-14 17:30 | 952.25 (+3.78%) | ||
| First quarter earnings results for 2027 | 2026-08-14 | 952.25 (+3.78%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-29 16:30 | 1,175.60 (-1.78%) |
Show
Entries
Natco Pharma Ltd Frequently Asked Questions
What is Natco Pharma Ltd(BOM:524816)'s stock price today?
The current price of BOM:524816 is ₹813.20. The 52 week high of BOM:524816 is ₹1226.10 and 52 week low is ₹789.30.
When is next earnings date of Natco Pharma Ltd(BOM:524816)?
The next earnings date of Natco Pharma Ltd(BOM:524816) is 2026-11-13 Est..
Does Natco Pharma Ltd(BOM:524816) pay dividends? If so, how much?
The Dividend Yield %  of Natco Pharma Ltd(BOM:524816) is 0.8% (As of Today), Highest Dividend Payout Ratio of Natco Pharma Ltd(BOM:524816) was 0.55. The lowest was 0.06. And the median was 0.18. The  Forward Dividend Yield % of Natco Pharma Ltd(BOM:524816) is 0.74%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Breckenridge launches Pomalidomide Capsules, strengthening its oncology portfolio | 2026-03-02 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers